^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Synovial Sarcoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Oncotarget
    Title:

    Intrathoracic synovial sarcoma with BRAF V600E mutation

    Published date:
    07/07/2023
    Excerpt:
    We report a case of 15-year-old boy with intrathoracic synovial sarcoma who relapsed after standard chemotherapy, surgery and radiotherapy. The molecular analysis of the tumour identified a BRAF V600E mutation…The patient underwent selective BRAF inhibitor Vemurafenib treatment achieving partial response (PR) with a progression free survival (PFS) ratio of 1.6 months and an overall survival of 19 months, alive in continuous PR.
    DOI:
    https://doi.org/10.18632/oncotarget.28475
    Test:
    TruSight Oncology 500 Assay